Objective:
To review new topical prescription therapies for presbyopia and dry eye disease.
Key Findings:
- Pilocarpine showed over 52% of patients achieving 20/40 DCNVA or better within 15 days (P<.0001).
- Aceclidine demonstrated a rapid onset of effect with 71% of participants achieving significant near vision improvement (P<.0001).
- Acoltremon met primary endpoints in phase 3 trials with significant improvements in tear production and symptom scores (P<.0001).
Interpretation:
New therapies like pilocarpine, aceclidine, and acoltremon provide effective treatment options for presbyopia and dry eye disease, with varying mechanisms and dosing regimens.
Limitations:
- Adverse events reported include headache, instillation site pain, and dim vision. Caution is advised for patients with specific conditions such as iritis and other ocular pathologies.
Conclusion:
Topical miotics and neuromodulators expand treatment options for presbyopia and dry eye, with ongoing investigations into additional therapies like qASED and reproxalap.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
